Author: Roshanravan, Neda; Seif, Farhad; Ostadrahimi, Alireza; Pouraghaei, Mahboub; Ghaffari, Samad
Title: Targeting Cytokine Storm to Manage Patients with COVID-19: A Mini-Review Cord-id: cv8r9pbl Document date: 2020_6_19
ID: cv8r9pbl
Snippet: Abstract Corona Virus Disease 2019 (COVID-19) pandemic is rapidly spreading all over the world. Excessive immune responses trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests that the modulation of systemic immune responses may have a potential role in the treatment of patients with
Document: Abstract Corona Virus Disease 2019 (COVID-19) pandemic is rapidly spreading all over the world. Excessive immune responses trigger life-threatening cytokine release syndrome (CRS) which can result in overproduction of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), and IL-1β with different pro-inflammatory roles. Anecdotal evidence suggests that the modulation of systemic immune responses may have a potential role in the treatment of patients with COVID-19. Given the importance of the issue and the lack of therapeutic treatment or vaccine; anti-cytokine therapy such as IL-6, TNFα and IL-1 antagonists have been suggested for the alleviation of hyper-inflammation status in these patients. In this mini-review, we addressed the inflammatory pathways of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its relationship with the host cytokine storm. Furthermore, the proposed therapeutic options to reverse hyper-inflammation in infected patients were mentioned.
Search related documents:
Co phrase search for related documents- acute sars cov respiratory syndrome coronavirus and adaptive immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute sars cov respiratory syndrome coronavirus and adaptive immune system sars stimulate innate: 1
- acute sars cov respiratory syndrome coronavirus and lung epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute sars cov respiratory syndrome coronavirus and lung lesion: 1, 2, 3, 4, 5, 6, 7, 8
- acute sars cov respiratory syndrome coronavirus and lymph spleen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute sars cov respiratory syndrome coronavirus and lymph spleen node: 1, 2, 3
- acute sars cov respiratory syndrome coronavirus and lymphoid organ: 1
- acute sars cov respiratory syndrome coronavirus and lymphopenia lymphocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute sars cov respiratory syndrome coronavirus and macrophage monocyte: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- adaptive immune response and lung epithelial cell: 1
- adaptive immune response and lymph spleen: 1, 2, 3
- adaptive immune response and lymph spleen node: 1
- adaptive immune response and lymphoid organ: 1
- adaptive immune response and macrophage monocyte: 1, 2, 3
- adaptive immune system and macrophage monocyte: 1, 2
- lung epithelial cell and macrophage monocyte: 1
- lymph spleen and macrophage monocyte: 1, 2, 3
- lymphopenia lymphocyte and macrophage monocyte: 1
Co phrase search for related documents, hyperlinks ordered by date